<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642460</url>
  </required_header>
  <id_info>
    <org_study_id>WA18221</org_study_id>
    <secondary_id>2007-000872-18</secondary_id>
    <nct_id>NCT00642460</nct_id>
  </id_info>
  <brief_title>A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)</brief_title>
  <official_title>A Randomized, Placebo-controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA), With an Open-label Extension to Examine the Long Term Use of Tocilizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in
      patients with active systemic juvenile idiopathic arthritis (sJIA) who have an inadequate
      clinical response to NSAIDs and corticosteroids. In Part I of the study patients will be
      randomized 2:1 to receive iv infusions of RoActemra/Actemra (8mg/kg iv for patients &gt;=30kg,
      or 12mg/kg for patients &lt;30kg) or placebo, every 2 weeks. Stable NSAIDs and methotrexate will
      be continued throughout. After 12 weeks of double-blind treatment, all patients will have the
      option to enter Part II of the study to receive open-label treatment with RoActemra/Actemra
      for a further 92 weeks, followed by a 3-year continuation of the study in Part III in which,
      for patients who meet specific criteria, an optional alternative dosing schedule decreasing
      the study drug administration frequency will be introduced. Anticipated time on study
      treatment is up to 5 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part I: Percentage of Participants With ≥30% Improvement in Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Core Set and Absence of Fever</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Percentage of participants with ≥30% improvement in ACR core set consisting of 6 components: 1) Physician's global assessment of disease activity Visual Analog Scale (VAS), 2) Parent/Patient global assessment of overall well-being VAS, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate, and 6) Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) consisting of 30 questions in 8 domains.
Absence of fever was defined as no diary temperature recording ≥37.5° Celsius in the preceding seven days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Percentage of Participants With Decreases in Oral Corticosteroid Dose at Week 104</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>Percentage of participants with ≥20 percent, ≥50 percent, ≥75 percent and ≥90 percent decreases in oral corticosteroid dose (mg/kg/day) from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part I: Percentage of Participants With JIA Core Set ACR 30/50/70/90 Response at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The six JIA ACR components consist of: 1) Physician's global assessment of disease activity, 2) Parent/Patient global assessment of overall well-being, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate, and 6) CHAQ-DI.
At an assessment visit a JIA ACR30/50/70/90 response in comparison to Baseline is defined as: At least three of the six JIA ACR core components improving by at least 30%/50%/70%/90% and no more than one of the remaining JIA ACR core components worsening by more than 30%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Physician's Global Assessment of Disease Activity</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Physician's Global Assessment of disease activity is a Visual Analog Scale. The scale is 0 to 100 mm horizontal scale, the extreme left end of the line represents 'arthritis inactive' (i.e. symptom-free and no arthritis symptoms) and the extreme right end represents 'arthritis very active'. This item is completed by the treating physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Parent/Patient Global Assessment of Overall Well-being</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Parent/Patient global assessment of overall well-being is a VAS. The scale is a 0 to 100 mm horizontal scale, the extreme left end of the line represents 'very well' (i.e. symptom-free and no arthritis disease activity) and the extreme right end represents 'very poor' (i.e. maximum arthritis disease activity). This item is completed by the patient or parent/guardian as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Maximum Number of Joints With Active Arthritis</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The maximum number of joints with active arthritis is 71 and these are defined as those in the joint assessment with: swelling present or pain present and limitation of motion.
The joint assessment is performed by an independent assessor, who is not the treating physician, blinded to all other aspects of the patient's efficacy and safety data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Number of Joints With Limitation of Movement</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The maximum number of joints with limitation of movement is 67 and these are defined as those in the joint assessment with 'limitation of motion'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Erythrocyte Sedimentation Rate</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Erythrocyte Sedimentation Rate (ESR) is an acute phase reactant measured in mm/hour.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Childhood Health Assessment Questionnaire Disability Index (CHAQ-DI)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Functional ability is assessed using the CHAQ-DI. The questionnaire consists of 30 questions referring to eight domains; dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain has at least two component questions and if applicable to the patient there are four possible responses (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do).
The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Percentage of Participants With Fever Due to Systemic Juvenile Idiopathic Arthritis (sJIA) at Baseline Who Are Free of Fever at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Fever free was defined as no diary temperature recording ≥37.5° Celsius in the preceding fourteen days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Percentage of Participants With Changes in Laboratory Indicators: High-sensitivity C-Reactive Protein(hsCRP), Hemoglobin (Hb), Platelets and Leukocytes From Abnormal at Baseline to Normal at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Percentage of participants with a change from an elevated hsCRP value at baseline to a normal hsCRP value at week 12; a change from anemia (low Hemoglobin) at baseline to a normal hemoglobin value at week 12; a change from thrombocytosis (elevated platelets) at baseline to a normal platelet value at week 12; a change from leukocytosis (elevated white blood cell count) at baseline to a normal white blood cell count at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Percentage of Participants With Concomitant Corticosteroid Reduction</measure>
    <time_frame>Week 6 or Week 8, Week 12</time_frame>
    <description>The percentage of participants receiving oral corticosteroids(CS) with a JIA ACR70 response at week 6 or Week 8 who reduced their oral CS dose by at least 20% without subsequent JIA ACR30 flare or occurrence of systemic symptoms at week 12.
At an assessment visit a JIA ACR70 response is defined as: At least three of the six JIA ACR core components improving by at least 70% and no more than one of the remaining JIA ACR core components worsening by more than 30%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Change From Baseline in the Pain Visual Analog Scale (VAS) at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Participants rated their pain by placing a horizontal line on a Visual Analog Scale on a scale of 0 (no pain)- 100 mm (severe pain). The score at 12 weeks minus the score at baseline. A negative number indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Percentage of Patients With Minimally Important Improvement in CHAQ-DI Score at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Percentage of patients who had at least a 0.13 improvement in CHAQ-DI score from Baseline to Week 12.
The CHAQ-DI questionnaire consists of 30 questions referring to eight domains; dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain has at least two component questions and if applicable to the patient there are four possible responses (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Percentage of Patients With Rash at Baseline Who Are Free From Rash at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Percentage of participants who had a rash characteristic of sJIA in the 14 days prior to the baseline visit but no rash characteristic of sJIA in the 14 days preceding the Week 12 visit day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Percentage of Patients With Anemia at Baseline With a ≥10 g/L Increase in Hemoglobin at Week 6 and Week 12</measure>
    <time_frame>Baseline, Week 6 and Week 12</time_frame>
    <description>Part I: Percentage of patients who had anemia (hemoglobin &lt;lower level normal based on sex and age) at Baseline and a ≥10 g/L increase in hemoglobin at Week 6 and at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Percentage of Participants With JIA ACR70 and JIA ACR90 Responses Week 104</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>The six JIA ACR components consist of: 1)Physician's global assessment of disease activity, 2)Parent/Patient global assessment of overall well-being, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate, and 6) CHAQ-DI.
At an assessment visit a JIA ACR70/90 response in comparison to Baseline is defined as: At least three of the six JIA ACR core components improving by at least 70%/90% and no more than one of the remaining JIA ACR core components worsening by more than 30%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Number of Active Joints at Week 104</measure>
    <time_frame>Week 104</time_frame>
    <description>Seventy-one joints were assessed for signs of active arthritis. The mean number of joints with signs of active arthritis is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Percentage of Participants With no Active Joints at Week 104</measure>
    <time_frame>Week 104</time_frame>
    <description>Seventy-one joints were assessed for signs of active arthritis. The percentage of participants with no signs of active arthritis is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Percentage of Participants With Inactive Disease at Week 104</measure>
    <time_frame>Week 104</time_frame>
    <description>Criteria for Inactive Disease:
1) No joints with active arthritis, 2) No fever, rash, serositis, splenomegaly, hepatomegaly (by physical exam) or generalized lymphadenopathy attributable to systemic juvenile idiopathic arthritis (sJIA), 3) Normal Erythrocyte Sedimentation Rate (&lt;20 mm/hour), 4) Physician's global assessment of disease activity Visual Analog Scale (VAS) indicates no disease activity (where no disease activity is considered to be a score ≤10 mm on a 100 mm VAS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) Score at Week 104</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>Functional ability is assessed using the CHAQ-DI. The questionnaire consists of 30 questions referring to eight domains; dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain has at least two component questions and if applicable to the patient there are four possible responses (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do).
The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Percentage of Participants With Oral Corticosteroid Cessation at Week 104</measure>
    <time_frame>Baseline, Week 104</time_frame>
    <description>Percentage is based on only those participants who were on oral corticosteroid at baseline and reached a nominal visit day on which dose was calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Rate of Serious Adverse Events (SAEs), Serious Infection Adverse Events (AEs), Related SAEs, Macrophage Activation Syndrome, AEs Leading to Withdrawal and Deaths Per 100 Patient Years to Week 104</measure>
    <time_frame>104 Weeks</time_frame>
    <description>Rate of SAEs, Rate of Serious Infection AEs, Rate of Related SAEs (remotely, possibly, probably) to Tocilizumab (TCZ), Rate of Macrophage Activation Syndrome, Rate of AEs leading to withdrawal and Rate of deaths per 100 patient years (PY) were calculated using the formula:
Number of Patient Events / Duration in study (years) * 100.
Multiple occurrences of the same AE in one individual are counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part III: Percentage of Participants With at Least 30%, 50%, 70%, and 90% Improvement in JIA Core Set According to ACR</measure>
    <time_frame>Weeks 104, 116, 128, 140, 152, 164, 176, 188, 200, 212, 224, 236, 248 and 260</time_frame>
    <description>Percentage of participants with ≥30%, 50%, 70%, and 90% improvement in ACR core set consisting of 6 components: 1) Physician's global assessment of disease activity VAS, 2) Parent/Patient global assessment of overall well-being VAS, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate, and 6) CHAQ-DI consisting of 30 questions in 8 domains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part III: Percentage of Participants Who Maintain JIA ACR30, JIA ACR50, JIA ACR70, JIA ACR90 Response for 6 Months Previous to the Specified Week</measure>
    <time_frame>Weeks 104, 116, 128, 140, 152, 164, 176, 188, 200, 212, 224, 236, 248 and 260</time_frame>
    <description>JIA ACR core set consisting of 6 components: 1) Physician's global assessment of disease activity VAS, 2) Parent/Patient global assessment of overall well-being VAS, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate, and 6) CHAQ-DI consisting of 30 questions in 8 domains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part III: Doses of Oral Corticosteroids</measure>
    <time_frame>Baseline and Weeks 104, 116, 128, 140, 152, 164, 176, 188, 200, 212, 224, 236, 248 and 260</time_frame>
    <description>Oral corticosteroid values summarized are based on average daily dose on the nominal study day. The prednisone equivalent is used in calculation of oral corticosteroid dose. Participants who withdrew are excluded at the the visit of withdrawal and all subsequent visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part III: Percentage of Participants on Corticosteroids at Baseline Able to Discontinue Corticosteroids by Weeks 104,116, 128, 140, 152, 164, 176, 188, 200, 212, 224, 236, 248, and 260</measure>
    <time_frame>Weeks 104,116, 128, 140, 152, 164, 176, 188, 200, 212, 224, 236, 248, and 260</time_frame>
    <description>Values summarized are based on average daily dose on the nominal study day. The prednisone equivalent is used in calculation of oral corticosteroid dose. Participants who withdrew are excluded at the timepoint of this event and at all subsequent visits.
Baseline considered first dose of study treatment. Data presented up to entry into the Alternative Dosing Schedule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part III: Percentage of Participants With a &gt;=20/50/75/90% Decrease From Baseline in Oral Corticosteroid Dose at Visits</measure>
    <time_frame>Every 2 weeks from Week 104 to Week 260</time_frame>
    <description>Values summarized are based on average daily dose on the nominal study day. The prednisone equivalent is used in calculation of oral corticosteroid dose. Participants who withdrew are excluded at the timepoint of this event and at all subsequent visits.
Baseline considered first dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part III: Percentage of Participants With Inactive Disease</measure>
    <time_frame>Weeks 104, 116, 128, 140, 152, 164, 188, 200, 212, 224,236,248 and 260</time_frame>
    <description>Participants who previously withdrew are excluded.
Responders are participants who met all of the following criteria for inactive disease at the visit assessment day:
i. Number of active joints = 0. ii. Absence of lymphadenopathy, hepatomegaly or splenomegaly in the nearest non-missing physical examination prior to or after the week assessment day. This could include results outside of the time window.
iii. Absence of symptomatic serositis adverse event. iv. In the 14 days preceding the week assessment day no fever (temperature &gt;=37.5 C) or rash characteristic of sJIA.
v. Normal ESR as defined by an ESR &lt;20 mm/hr regardless of age and sex. vi. Physician global assessment VAS &lt;=10. LOCF rule applied to missing number of active joints, ESR and Physician global assessment VAS.
Data presented up to the point of entry into the Alternative Dosing Schedule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part III: Percentage of Participants in Clinical Remission</measure>
    <time_frame>Weeks 116, 128, 140, 152, 164, 188, 200, 212, 224,236,248 and 260</time_frame>
    <description>Patients who previously withdrew are excluded Responders are patients who met all of the following criteria for inactive disease at all visits in the 6 months (180 days) prior to and including the visit assessment day: i. Number of active joints = 0. ii. Absence of lymphadenopathy, hepatomegaly or splenomegaly in the nearest non-missing physical examination prior to or after the week assessment day. This could include results outside of the time window.
iii. Absence of symptomatic serositis adverse event. iv. In the 14 days preceding the week assessment day no fever (temperature &gt;=37.5 C) or rash characteristic of sJIA. v. Normal ESR as defined by an ESR &lt;20 mm/hr regardless of age and sex.
vi. iv. Physician global assessment VAS &lt;=10. LOCF rule applied to missing number of active joints, ESR and Physician global assessment VAS. ESR = Erythrocyte Sedimentation Rate. VAS = Visual Analogue Scale. Data presented up to the point of entry into the Alternative Dosing Schedule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part III: Percentage of Participants on Corticosteroids at Baseline in Clinical Remission Off All Oral Corticosteroids for 6 Months Prior to Specified Visits</measure>
    <time_frame>Weeks 116, 128, 140, 152, 164, 188, 200, 212, 224,236,248 and 260</time_frame>
    <description>There were 4 levels of clinical remission defined while the patient remained on tocilizumab as defined below.. After level 1, each successive level required that all the previous level criteria be met:
Level 1: inactive disease criteria have been met at all assessments in the last 6 months (180 days) preceding the timepoint assessment day Level 2: level 1 criteria and no oral corticosteroids received in the last 6 months (180 days) preceding the timepoint assessment day Level 3: level 2 criteria and no methotrexate received in the last 6 months (180 days) preceding the timepoint assessment day Level 4: level 3 criteria and no NSAIDs received for sJIA in the last 6 months (180 days) preceding the timepoint assessment day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part III: Percentage of Participants on Methotrexate At Baseline in Clinical Remission Off Corticosteroids and Methotrexate for 6 Months Prior to Specified Visits</measure>
    <time_frame>Weeks 116, 128, 140, 152, 164, 188, 200, 212, 224,236,248 and 260</time_frame>
    <description>There were 4 levels of clinical remission defined while the patient remained on tocilizumab as defined below.. After level 1, each successive level required that all the previous level criteria be met:
Level 1: inactive disease criteria have been met at all assessments in the last 6 months (180 days) preceding the timepoint assessment day Level 2: level 1 criteria and no oral corticosteroids received in the last 6 months (180 days) preceding the timepoint assessment day Level 3: level 2 criteria and no methotrexate received in the last 6 months (180 days) preceding the timepoint assessment day Level 4: level 3 criteria and no NSAIDs received for sJIA in the last 6 months (180 days) preceding the timepoint assessment day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part III: Percentage of Participants in Clinical Remission Off All Arthritis Medications Except Tocilizumab for 6 Months Prior to Specified Visits</measure>
    <time_frame>Weeks 116, 128, 140, 152, 164, 188, 200, 212, 224,236,248 and 260</time_frame>
    <description>There were 4 levels of clinical remission defined while the patient remained on tocilizumab as defined below.. After level 1, each successive level required that all the previous level criteria be met:
Level 1: inactive disease criteria have been met at all assessments in the last 6 months (180 days) preceding the timepoint assessment day Level 2: level 1 criteria and no oral corticosteroids received in the last 6 months (180 days) preceding the timepoint assessment day Level 3: level 2 criteria and no methotrexate received in the last 6 months (180 days) preceding the timepoint assessment day Level 4: level 3 criteria and no NSAIDs received for sJIA in the last 6 months (180 days) preceding the timepoint assessment day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part III: Percentage of Participants Who Developed Antibodies To Tocilizumab During Weeks 104 to 260</measure>
    <time_frame>Every 2 weeks from Week 104 to 260</time_frame>
    <description>Human antibodies against human antibodies (HAHA), anti-tocilizumab antibodies were assessed by immunogenicity techniques from blood samples drawn every two weeks during Part III of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part III: Percentage of Participants Who Developed Anti-TCZ Antibodies Associated With The Occurrence of Drug Hypersensitivity Reactions.</measure>
    <time_frame>Every 2 weeks from Week 104 to 260</time_frame>
    <description>Human antibodies against human antibodies (HAHA), anti-tocilizumab antibodies were assessed by immunogenicity techniques from blood samples drawn every two weeks during Part III of the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tocilizumab [RoActemra/Actemra]</intervention_name>
    <description>8mg/kg (patients&gt;=30kg) or 12mg/kg (patients &lt;30kg) iv every 2 weeks. In Part III, administration frequency may be reduced to every 3 and every 4 weeks, respectively, according to an optional alternative dosing schedule.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>iv every 2 weeks for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-steroidal anti-inflammatory drugs (NSAIDs)</intervention_name>
    <description>as prescribed</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>as prescribed</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corticosteroids</intervention_name>
    <description>orally, as prescribed</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 2-17 years of age

          -  Systemic juvenile idiopathic arthritis with &gt;= 6 months persistent activity

          -  Presence of active disease (&gt;=5 active joints, or &gt;=2 active joints + fever +
             steroids)

          -  Inadequate clinical response to nonsteroidal anti-inflammatory drugs (NSAIDs) and
             corticosteroids due to toxicity or lack of efficacy

        Exclusion Criteria:

          -  Wheelchair-bound or bed-ridden

          -  Any other autoimmune, rheumatic disease or overlap syndrome other than systemic
             juvenile idiopathic arthritis

          -  Intravenous long-acting corticosteroids or intra-articular corticosteroids within 4
             weeks of baseline, or throughout study

          -  Disease-modifying antirheumatic drugs (DMARDs), other than methotrexate

          -  Previous treatment with tocilizumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202-3906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>1270</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Plata</city>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Subiaco</city>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20551-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3J 3G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <zip>121-09</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bremen</city>
        <zip>28205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sankt Augustin</city>
        <zip>53757</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miexico City</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Utrecht</city>
        <zip>3584 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kraków</city>
        <zip>31-503</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Piestany</city>
        <zip>921 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Esplugas de Llobregat</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goeteborg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>WC1N IEH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2008</study_first_posted>
  <results_first_submitted>September 16, 2011</results_first_submitted>
  <results_first_submitted_qc>September 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 26, 2011</results_first_posted>
  <last_update_submitted>June 24, 2016</last_update_submitted>
  <last_update_submitted_qc>June 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study consists of 3 parts. Part I: a 12 week double-blind placebo controlled study followed by Part II: a 92 week single arm open-label extension study followed by Part III: a 3 year open label continuation study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tocilizumab_8 mg/kg</title>
          <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part I and every 2 weeks for 92 weeks in Part II.
Participants remained on their prescribed standard of care treatment with non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate and corticosteroids if applicable.</description>
        </group>
        <group group_id="P2">
          <title>Tocilizumab_12 mg/kg</title>
          <description>Tocilizumab 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part I and every 2 weeks for 92 weeks in Part II.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo iv every 2 weeks for 12 weeks in Part 1. Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
        </group>
        <group group_id="P4">
          <title>Tocilizumab Switchers</title>
          <description>Tocilizumab Switchers includes all participants who changed their dose either Tocilizumab 8 mg/kg or 12 mg/kg intravenous (iv) every 2 weeks in Part II.
Participants remained on their prescribed standard of care treatment with non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate and corticosteroids if applicable.</description>
        </group>
        <group group_id="P5">
          <title>Participants ≥30 kg</title>
          <description>Tocilizumab 8 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
        </group>
        <group group_id="P6">
          <title>Participants &lt;30 kg</title>
          <description>Tocilizumab 12 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part I: 12 Week Double-Blind</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Part I : Intent-to-treat</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part II: Open-Label Up to Week 92</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52">Includes Participants who received Open-Label in Part II or Open-Label escape therapy in Part I.</participants>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="0">Placebo group received open-label Tocilizumab 8 mg/kg or 12 mg/kg based on body weight in Part II.</participants>
                <participants group_id="P4" count="20">19 Participants switched from 12 mg/kg to 8 mg/kg and 1 Participant switched from 8mg/kg to 12 mg/kg</participants>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Part II: Intent-to-treat</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient therapeutic response</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused treatment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to return</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part III: Open-Label Up to Week 260</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="53"/>
                <participants group_id="P6" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient therapeutic response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tocilizumab</title>
          <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate and corticosteroids if applicable.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo iv every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="112"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2 to 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13 to 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part I: Percentage of Participants With ≥30% Improvement in Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Core Set and Absence of Fever</title>
        <description>Percentage of participants with ≥30% improvement in ACR core set consisting of 6 components: 1) Physician's global assessment of disease activity Visual Analog Scale (VAS), 2) Parent/Patient global assessment of overall well-being VAS, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate, and 6) Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) consisting of 30 questions in 8 domains.
Absence of fever was defined as no diary temperature recording ≥37.5° Celsius in the preceding seven days.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-treat population includes all participants who had at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo iv every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Percentage of Participants With ≥30% Improvement in Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Core Set and Absence of Fever</title>
          <description>Percentage of participants with ≥30% improvement in ACR core set consisting of 6 components: 1) Physician's global assessment of disease activity Visual Analog Scale (VAS), 2) Parent/Patient global assessment of overall well-being VAS, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate, and 6) Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) consisting of 30 questions in 8 domains.
Absence of fever was defined as no diary temperature recording ≥37.5° Celsius in the preceding seven days.</description>
          <population>Intent-to-treat population includes all participants who had at least one dose of study drug.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3"/>
                    <measurement group_id="O2" value="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part II: Percentage of Participants With Decreases in Oral Corticosteroid Dose at Week 104</title>
        <description>Percentage of participants with ≥20 percent, ≥50 percent, ≥75 percent and ≥90 percent decreases in oral corticosteroid dose (mg/kg/day) from baseline.</description>
        <time_frame>Baseline, Week 104</time_frame>
        <population>Includes only participants on oral corticosteroids at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients &gt;=30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Percentage of Participants With Decreases in Oral Corticosteroid Dose at Week 104</title>
          <description>Percentage of participants with ≥20 percent, ≥50 percent, ≥75 percent and ≥90 percent decreases in oral corticosteroid dose (mg/kg/day) from baseline.</description>
          <population>Includes only participants on oral corticosteroids at baseline.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥20 percent decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥50 percent decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥75 percent decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥90 percent decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Percentage of Participants With JIA Core Set ACR 30/50/70/90 Response at Week 12</title>
        <description>The six JIA ACR components consist of: 1) Physician's global assessment of disease activity, 2) Parent/Patient global assessment of overall well-being, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate, and 6) CHAQ-DI.
At an assessment visit a JIA ACR30/50/70/90 response in comparison to Baseline is defined as: At least three of the six JIA ACR core components improving by at least 30%/50%/70%/90% and no more than one of the remaining JIA ACR core components worsening by more than 30%.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-treat population includes all randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo iv every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Percentage of Participants With JIA Core Set ACR 30/50/70/90 Response at Week 12</title>
          <description>The six JIA ACR components consist of: 1) Physician's global assessment of disease activity, 2) Parent/Patient global assessment of overall well-being, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate, and 6) CHAQ-DI.
At an assessment visit a JIA ACR30/50/70/90 response in comparison to Baseline is defined as: At least three of the six JIA ACR core components improving by at least 30%/50%/70%/90% and no more than one of the remaining JIA ACR core components worsening by more than 30%.</description>
          <population>Intent-to-treat population includes all randomized participants who received at least one dose of study drug.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>JIA ACR30 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7"/>
                    <measurement group_id="O2" value="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JIA ACR50 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3"/>
                    <measurement group_id="O2" value="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JIA ACR70 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7"/>
                    <measurement group_id="O2" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JIA ACR90 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3"/>
                    <measurement group_id="O2" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Physician's Global Assessment of Disease Activity</title>
        <description>Physician's Global Assessment of disease activity is a Visual Analog Scale. The scale is 0 to 100 mm horizontal scale, the extreme left end of the line represents ‘arthritis inactive’ (i.e. symptom-free and no arthritis symptoms) and the extreme right end represents ‘arthritis very active’. This item is completed by the treating physician.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-treat population. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are excluded. Last observation carried forward (LOCF) rule applied to missing JIA ACR core set components at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo iv every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Physician's Global Assessment of Disease Activity</title>
          <description>Physician's Global Assessment of disease activity is a Visual Analog Scale. The scale is 0 to 100 mm horizontal scale, the extreme left end of the line represents ‘arthritis inactive’ (i.e. symptom-free and no arthritis symptoms) and the extreme right end represents ‘arthritis very active’. This item is completed by the treating physician.</description>
          <population>Intent-to-treat population. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are excluded. Last observation carried forward (LOCF) rule applied to missing JIA ACR core set components at Week 12.</population>
          <units>Percentage change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69.6"/>
                    <measurement group_id="O2" value="-41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Parent/Patient Global Assessment of Overall Well-being</title>
        <description>The Parent/Patient global assessment of overall well-being is a VAS. The scale is a 0 to 100 mm horizontal scale, the extreme left end of the line represents ‘very well’ (i.e. symptom-free and no arthritis disease activity) and the extreme right end represents ‘very poor’ (i.e. maximum arthritis disease activity). This item is completed by the patient or parent/guardian as appropriate.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-treat population. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are excluded. LOCF rule applied to missing JIA ACR core set components at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo iv every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Parent/Patient Global Assessment of Overall Well-being</title>
          <description>The Parent/Patient global assessment of overall well-being is a VAS. The scale is a 0 to 100 mm horizontal scale, the extreme left end of the line represents ‘very well’ (i.e. symptom-free and no arthritis disease activity) and the extreme right end represents ‘very poor’ (i.e. maximum arthritis disease activity). This item is completed by the patient or parent/guardian as appropriate.</description>
          <population>Intent-to-treat population. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are excluded. LOCF rule applied to missing JIA ACR core set components at Week 12.</population>
          <units>Percentage change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65.8"/>
                    <measurement group_id="O2" value="-1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Maximum Number of Joints With Active Arthritis</title>
        <description>The maximum number of joints with active arthritis is 71 and these are defined as those in the joint assessment with: swelling present or pain present and limitation of motion.
The joint assessment is performed by an independent assessor, who is not the treating physician, blinded to all other aspects of the patient’s efficacy and safety data.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-treat population. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are excluded. LOCF rule applied to missing JIA ACR core set components at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo iv every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Maximum Number of Joints With Active Arthritis</title>
          <description>The maximum number of joints with active arthritis is 71 and these are defined as those in the joint assessment with: swelling present or pain present and limitation of motion.
The joint assessment is performed by an independent assessor, who is not the treating physician, blinded to all other aspects of the patient’s efficacy and safety data.</description>
          <population>Intent-to-treat population. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are excluded. LOCF rule applied to missing JIA ACR core set components at Week 12.</population>
          <units>Percentage change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.6"/>
                    <measurement group_id="O2" value="-37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Number of Joints With Limitation of Movement</title>
        <description>The maximum number of joints with limitation of movement is 67 and these are defined as those in the joint assessment with ‘limitation of motion’.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-treat population. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are excluded. LOCF rule applied to missing JIA ACR core set components at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo iv every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Number of Joints With Limitation of Movement</title>
          <description>The maximum number of joints with limitation of movement is 67 and these are defined as those in the joint assessment with ‘limitation of motion’.</description>
          <population>Intent-to-treat population. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are excluded. LOCF rule applied to missing JIA ACR core set components at Week 12.</population>
          <units>Percentage change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.6"/>
                    <measurement group_id="O2" value="-22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Erythrocyte Sedimentation Rate</title>
        <description>Erythrocyte Sedimentation Rate (ESR) is an acute phase reactant measured in mm/hour.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-treat population. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are excluded. LOCF rule applied to missing JIA ACR core set components at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo iv every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Erythrocyte Sedimentation Rate</title>
          <description>Erythrocyte Sedimentation Rate (ESR) is an acute phase reactant measured in mm/hour.</description>
          <population>Intent-to-treat population. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are excluded. LOCF rule applied to missing JIA ACR core set components at Week 12.</population>
          <units>Percentage change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-88.2"/>
                    <measurement group_id="O2" value="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Childhood Health Assessment Questionnaire Disability Index (CHAQ-DI)</title>
        <description>Functional ability is assessed using the CHAQ-DI. The questionnaire consists of 30 questions referring to eight domains; dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain has at least two component questions and if applicable to the patient there are four possible responses (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do).
The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-treat population. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are excluded. LOCF rule applied to missing JIA ACR core set components at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo iv every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Percentage Change From Baseline in JIA Core Set ACR Score Component: Childhood Health Assessment Questionnaire Disability Index (CHAQ-DI)</title>
          <description>Functional ability is assessed using the CHAQ-DI. The questionnaire consists of 30 questions referring to eight domains; dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain has at least two component questions and if applicable to the patient there are four possible responses (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do).
The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst).</description>
          <population>Intent-to-treat population. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are excluded. LOCF rule applied to missing JIA ACR core set components at Week 12.</population>
          <units>Percentage change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.6"/>
                    <measurement group_id="O2" value="-10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Percentage of Participants With Fever Due to Systemic Juvenile Idiopathic Arthritis (sJIA) at Baseline Who Are Free of Fever at Week 12</title>
        <description>Fever free was defined as no diary temperature recording ≥37.5° Celsius in the preceding fourteen days.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Participants from the Intent-to-treat population (all randomized participants who received at least one dose of study drug) who had a fever due to Systemic Juvenile Idiopathic Arthritis at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo iv every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Percentage of Participants With Fever Due to Systemic Juvenile Idiopathic Arthritis (sJIA) at Baseline Who Are Free of Fever at Week 12</title>
          <description>Fever free was defined as no diary temperature recording ≥37.5° Celsius in the preceding fourteen days.</description>
          <population>Participants from the Intent-to-treat population (all randomized participants who received at least one dose of study drug) who had a fever due to Systemic Juvenile Idiopathic Arthritis at baseline.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4"/>
                    <measurement group_id="O2" value="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Percentage of Participants With Changes in Laboratory Indicators: High-sensitivity C-Reactive Protein(hsCRP), Hemoglobin (Hb), Platelets and Leukocytes From Abnormal at Baseline to Normal at Week 12</title>
        <description>Percentage of participants with a change from an elevated hsCRP value at baseline to a normal hsCRP value at week 12; a change from anemia (low Hemoglobin) at baseline to a normal hemoglobin value at week 12; a change from thrombocytosis (elevated platelets) at baseline to a normal platelet value at week 12; a change from leukocytosis (elevated white blood cell count) at baseline to a normal white blood cell count at week 12.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-treat population includes all randomized participants who received at least one dose of study drug. 'n' in each of the categories is the number of participants with data available at baseline and week 12 for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo iv every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Percentage of Participants With Changes in Laboratory Indicators: High-sensitivity C-Reactive Protein(hsCRP), Hemoglobin (Hb), Platelets and Leukocytes From Abnormal at Baseline to Normal at Week 12</title>
          <description>Percentage of participants with a change from an elevated hsCRP value at baseline to a normal hsCRP value at week 12; a change from anemia (low Hemoglobin) at baseline to a normal hemoglobin value at week 12; a change from thrombocytosis (elevated platelets) at baseline to a normal platelet value at week 12; a change from leukocytosis (elevated white blood cell count) at baseline to a normal white blood cell count at week 12.</description>
          <population>Intent-to-treat population includes all randomized participants who received at least one dose of study drug. 'n' in each of the categories is the number of participants with data available at baseline and week 12 for analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hsC-Reactive Protein (n=72,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6"/>
                    <measurement group_id="O2" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (n=50,29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets (n=52,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.4"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes (n=28,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Percentage of Participants With Concomitant Corticosteroid Reduction</title>
        <description>The percentage of participants receiving oral corticosteroids(CS) with a JIA ACR70 response at week 6 or Week 8 who reduced their oral CS dose by at least 20% without subsequent JIA ACR30 flare or occurrence of systemic symptoms at week 12.
At an assessment visit a JIA ACR70 response is defined as: At least three of the six JIA ACR core components improving by at least 70% and no more than one of the remaining JIA ACR core components worsening by more than 30%.</description>
        <time_frame>Week 6 or Week 8, Week 12</time_frame>
        <population>Participants from the Intent-to-treat population (all randomized participants who received at least one dose of study drug) who were taking oral corticosteroids.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo iv every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Percentage of Participants With Concomitant Corticosteroid Reduction</title>
          <description>The percentage of participants receiving oral corticosteroids(CS) with a JIA ACR70 response at week 6 or Week 8 who reduced their oral CS dose by at least 20% without subsequent JIA ACR30 flare or occurrence of systemic symptoms at week 12.
At an assessment visit a JIA ACR70 response is defined as: At least three of the six JIA ACR core components improving by at least 70% and no more than one of the remaining JIA ACR core components worsening by more than 30%.</description>
          <population>Participants from the Intent-to-treat population (all randomized participants who received at least one dose of study drug) who were taking oral corticosteroids.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                    <measurement group_id="O2" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Change From Baseline in the Pain Visual Analog Scale (VAS) at Week 12</title>
        <description>Participants rated their pain by placing a horizontal line on a Visual Analog Scale on a scale of 0 (no pain)- 100 mm (severe pain). The score at 12 weeks minus the score at baseline. A negative number indicates improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Participants from the Intent-to-treat population who had Pain VAS data available at baseline and week 12. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are excluded. LOCF rule applied to missing pain VAS at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo iv every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Change From Baseline in the Pain Visual Analog Scale (VAS) at Week 12</title>
          <description>Participants rated their pain by placing a horizontal line on a Visual Analog Scale on a scale of 0 (no pain)- 100 mm (severe pain). The score at 12 weeks minus the score at baseline. A negative number indicates improvement.</description>
          <population>Participants from the Intent-to-treat population who had Pain VAS data available at baseline and week 12. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are excluded. LOCF rule applied to missing pain VAS at Week 12.</population>
          <units>mm</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.0"/>
                    <measurement group_id="O2" value="-1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Percentage of Patients With Minimally Important Improvement in CHAQ-DI Score at Week 12</title>
        <description>Percentage of patients who had at least a 0.13 improvement in CHAQ-DI score from Baseline to Week 12.
The CHAQ-DI questionnaire consists of 30 questions referring to eight domains; dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain has at least two component questions and if applicable to the patient there are four possible responses (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Intent-to-treat Population. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are classified as non-responders.
LOCF rule applied to missing CHAQ-DI Scores at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo iv every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Percentage of Patients With Minimally Important Improvement in CHAQ-DI Score at Week 12</title>
          <description>Percentage of patients who had at least a 0.13 improvement in CHAQ-DI score from Baseline to Week 12.
The CHAQ-DI questionnaire consists of 30 questions referring to eight domains; dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain has at least two component questions and if applicable to the patient there are four possible responses (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do).</description>
          <population>Intent-to-treat Population. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are classified as non-responders.
LOCF rule applied to missing CHAQ-DI Scores at Week 12.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" lower_limit="67.9" upper_limit="86.8"/>
                    <measurement group_id="O2" value="18.9" lower_limit="6.3" upper_limit="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Percentage of Patients With Rash at Baseline Who Are Free From Rash at Week 12</title>
        <description>Percentage of participants who had a rash characteristic of sJIA in the 14 days prior to the baseline visit but no rash characteristic of sJIA in the 14 days preceding the Week 12 visit day.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Participants from the Intent-to-treat population for whom data was available. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are classified as non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo iv every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Percentage of Patients With Rash at Baseline Who Are Free From Rash at Week 12</title>
          <description>Percentage of participants who had a rash characteristic of sJIA in the 14 days prior to the baseline visit but no rash characteristic of sJIA in the 14 days preceding the Week 12 visit day.</description>
          <population>Participants from the Intent-to-treat population for whom data was available. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are classified as non-responders.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" lower_limit="43.5" upper_limit="83.7"/>
                    <measurement group_id="O2" value="11.1" lower_limit="0.0" upper_limit="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Percentage of Patients With Anemia at Baseline With a ≥10 g/L Increase in Hemoglobin at Week 6 and Week 12</title>
        <description>Part I: Percentage of patients who had anemia (hemoglobin &lt;lower level normal based on sex and age) at Baseline and a ≥10 g/L increase in hemoglobin at Week 6 and at Week 12.</description>
        <time_frame>Baseline, Week 6 and Week 12</time_frame>
        <population>Participants from the Intent-to-treat population for whom hemoglobin data available. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are classified as non-responders.
LOCF rule applied to missing hemoglobin values at Week 6 and Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients ≥30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo iv every 2 weeks for 12 weeks in Part 1.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Percentage of Patients With Anemia at Baseline With a ≥10 g/L Increase in Hemoglobin at Week 6 and Week 12</title>
          <description>Part I: Percentage of patients who had anemia (hemoglobin &lt;lower level normal based on sex and age) at Baseline and a ≥10 g/L increase in hemoglobin at Week 6 and at Week 12.</description>
          <population>Participants from the Intent-to-treat population for whom hemoglobin data available. Patients who withdrew, received escape medication, or for whom the endpoint cannot be determined are classified as non-responders.
LOCF rule applied to missing hemoglobin values at Week 6 and Week 12.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.0" lower_limit="79.0" upper_limit="97.0"/>
                    <measurement group_id="O2" value="3.4" lower_limit="0.0" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.0" lower_limit="79.0" upper_limit="97.0"/>
                    <measurement group_id="O2" value="3.4" lower_limit="0.0" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part II: Percentage of Participants With JIA ACR70 and JIA ACR90 Responses Week 104</title>
        <description>The six JIA ACR components consist of: 1)Physician's global assessment of disease activity, 2)Parent/Patient global assessment of overall well-being, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate, and 6) CHAQ-DI.
At an assessment visit a JIA ACR70/90 response in comparison to Baseline is defined as: At least three of the six JIA ACR core components improving by at least 70%/90% and no more than one of the remaining JIA ACR core components worsening by more than 30%.</description>
        <time_frame>Baseline, Week 104</time_frame>
        <population>Participants from the Intent to Treat population who reached the time point plus patients who withdrew because of insufficient therapeutic response and are assumed to have been non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients &gt;=30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1 and every 2 weeks for 92 weeks in Part II.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Percentage of Participants With JIA ACR70 and JIA ACR90 Responses Week 104</title>
          <description>The six JIA ACR components consist of: 1)Physician's global assessment of disease activity, 2)Parent/Patient global assessment of overall well-being, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate, and 6) CHAQ-DI.
At an assessment visit a JIA ACR70/90 response in comparison to Baseline is defined as: At least three of the six JIA ACR core components improving by at least 70%/90% and no more than one of the remaining JIA ACR core components worsening by more than 30%.</description>
          <population>Participants from the Intent to Treat population who reached the time point plus patients who withdrew because of insufficient therapeutic response and are assumed to have been non-responders.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>JIA ACR70 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JIA ACR90 response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part II: Number of Active Joints at Week 104</title>
        <description>Seventy-one joints were assessed for signs of active arthritis. The mean number of joints with signs of active arthritis is reported.</description>
        <time_frame>Week 104</time_frame>
        <population>Participants from the Intent to Treat population who reached this time point. No data imputation is applied and patients with missing data are excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients &gt;=30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1 and every 2 weeks for 92 weeks in Part II.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Number of Active Joints at Week 104</title>
          <description>Seventy-one joints were assessed for signs of active arthritis. The mean number of joints with signs of active arthritis is reported.</description>
          <population>Participants from the Intent to Treat population who reached this time point. No data imputation is applied and patients with missing data are excluded.</population>
          <units>Active Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part II: Percentage of Participants With no Active Joints at Week 104</title>
        <description>Seventy-one joints were assessed for signs of active arthritis. The percentage of participants with no signs of active arthritis is reported.</description>
        <time_frame>Week 104</time_frame>
        <population>The Intent to Treat population in Part II includes 112 participants who received at least one dose of study drug. Only those participants who reached this time point are included in the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients &gt;=30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1 and every 2 weeks for 92 weeks in Part II.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Percentage of Participants With no Active Joints at Week 104</title>
          <description>Seventy-one joints were assessed for signs of active arthritis. The percentage of participants with no signs of active arthritis is reported.</description>
          <population>The Intent to Treat population in Part II includes 112 participants who received at least one dose of study drug. Only those participants who reached this time point are included in the analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part II: Percentage of Participants With Inactive Disease at Week 104</title>
        <description>Criteria for Inactive Disease:
1) No joints with active arthritis, 2) No fever, rash, serositis, splenomegaly, hepatomegaly (by physical exam) or generalized lymphadenopathy attributable to systemic juvenile idiopathic arthritis (sJIA), 3) Normal Erythrocyte Sedimentation Rate (&lt;20 mm/hour), 4) Physician’s global assessment of disease activity Visual Analog Scale (VAS) indicates no disease activity (where no disease activity is considered to be a score ≤10 mm on a 100 mm VAS).</description>
        <time_frame>Week 104</time_frame>
        <population>Participants from the Intent to Treat population who reached time point plus patients who withdrew because of insufficient therapeutic response and are assumed to have been nonresponders.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients &gt;=30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1 and every 2 weeks for 92 weeks in Part II.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Percentage of Participants With Inactive Disease at Week 104</title>
          <description>Criteria for Inactive Disease:
1) No joints with active arthritis, 2) No fever, rash, serositis, splenomegaly, hepatomegaly (by physical exam) or generalized lymphadenopathy attributable to systemic juvenile idiopathic arthritis (sJIA), 3) Normal Erythrocyte Sedimentation Rate (&lt;20 mm/hour), 4) Physician’s global assessment of disease activity Visual Analog Scale (VAS) indicates no disease activity (where no disease activity is considered to be a score ≤10 mm on a 100 mm VAS).</description>
          <population>Participants from the Intent to Treat population who reached time point plus patients who withdrew because of insufficient therapeutic response and are assumed to have been nonresponders.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part II: Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) Score at Week 104</title>
        <description>Functional ability is assessed using the CHAQ-DI. The questionnaire consists of 30 questions referring to eight domains; dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain has at least two component questions and if applicable to the patient there are four possible responses (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do).
The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst).</description>
        <time_frame>Baseline, Week 104</time_frame>
        <population>Participants from the Intent to Treat population who withdrew have been excluded at post withdrawal visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients &gt;=30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1 and every 2 weeks for 92 weeks in Part II.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) Score at Week 104</title>
          <description>Functional ability is assessed using the CHAQ-DI. The questionnaire consists of 30 questions referring to eight domains; dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain has at least two component questions and if applicable to the patient there are four possible responses (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do).
The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst).</description>
          <population>Participants from the Intent to Treat population who withdrew have been excluded at post withdrawal visits.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=112)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 (n=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part II: Percentage of Participants With Oral Corticosteroid Cessation at Week 104</title>
        <description>Percentage is based on only those participants who were on oral corticosteroid at baseline and reached a nominal visit day on which dose was calculated.</description>
        <time_frame>Baseline, Week 104</time_frame>
        <population>Participants from the Intent to Treat population who withdrew have been excluded at post withdrawal visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients &gt;=30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1 and every 2 weeks for 92 weeks in Part II.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Percentage of Participants With Oral Corticosteroid Cessation at Week 104</title>
          <description>Percentage is based on only those participants who were on oral corticosteroid at baseline and reached a nominal visit day on which dose was calculated.</description>
          <population>Participants from the Intent to Treat population who withdrew have been excluded at post withdrawal visits.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part II: Rate of Serious Adverse Events (SAEs), Serious Infection Adverse Events (AEs), Related SAEs, Macrophage Activation Syndrome, AEs Leading to Withdrawal and Deaths Per 100 Patient Years to Week 104</title>
        <description>Rate of SAEs, Rate of Serious Infection AEs, Rate of Related SAEs (remotely, possibly, probably) to Tocilizumab (TCZ), Rate of Macrophage Activation Syndrome, Rate of AEs leading to withdrawal and Rate of deaths per 100 patient years (PY) were calculated using the formula:
Number of Patient Events / Duration in study (years) * 100.
Multiple occurrences of the same AE in one individual are counted.</description>
        <time_frame>104 Weeks</time_frame>
        <population>Safety Population- all participants who received at least one dose of study drug and had 1 post-baseline safety assessment. Includes all safety data in the database up to the week 104 infusion based on the date of randomization for each patient. (Last date was 31 May 2011)</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab 8 mg/kg (for patients &gt;=30 kg) or 12 mg/kg (for patients &lt;30 kg) intravenous (iv) every 2 weeks for 12 weeks in Part 1 and every 2 weeks for 92 weeks in Part II.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Rate of Serious Adverse Events (SAEs), Serious Infection Adverse Events (AEs), Related SAEs, Macrophage Activation Syndrome, AEs Leading to Withdrawal and Deaths Per 100 Patient Years to Week 104</title>
          <description>Rate of SAEs, Rate of Serious Infection AEs, Rate of Related SAEs (remotely, possibly, probably) to Tocilizumab (TCZ), Rate of Macrophage Activation Syndrome, Rate of AEs leading to withdrawal and Rate of deaths per 100 patient years (PY) were calculated using the formula:
Number of Patient Events / Duration in study (years) * 100.
Multiple occurrences of the same AE in one individual are counted.</description>
          <population>Safety Population- all participants who received at least one dose of study drug and had 1 post-baseline safety assessment. Includes all safety data in the database up to the week 104 infusion based on the date of randomization for each patient. (Last date was 31 May 2011)</population>
          <units>Events per 100 patient year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious infection AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs related to TCZ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macrophage activation syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part III: Percentage of Participants With at Least 30%, 50%, 70%, and 90% Improvement in JIA Core Set According to ACR</title>
        <description>Percentage of participants with ≥30%, 50%, 70%, and 90% improvement in ACR core set consisting of 6 components: 1) Physician's global assessment of disease activity VAS, 2) Parent/Patient global assessment of overall well-being VAS, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate, and 6) CHAQ-DI consisting of 30 questions in 8 domains.</description>
        <time_frame>Weeks 104, 116, 128, 140, 152, 164, 176, 188, 200, 212, 224, 236, 248 and 260</time_frame>
        <population>The Part III intent-to-treat (ITT3) population consists of all participants who entered into Part III of the study and received at least one administration of tocilizumab during Part III.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants ≥30 kg</title>
            <description>Tocilizumab 8 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Participants &lt;30 kg</title>
            <description>Tocilizumab 12 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part III: Percentage of Participants With at Least 30%, 50%, 70%, and 90% Improvement in JIA Core Set According to ACR</title>
          <description>Percentage of participants with ≥30%, 50%, 70%, and 90% improvement in ACR core set consisting of 6 components: 1) Physician's global assessment of disease activity VAS, 2) Parent/Patient global assessment of overall well-being VAS, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate, and 6) CHAQ-DI consisting of 30 questions in 8 domains.</description>
          <population>The Part III intent-to-treat (ITT3) population consists of all participants who entered into Part III of the study and received at least one administration of tocilizumab during Part III.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 104 JIA ACR30 (n=42,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 JIA ACR50 (n=42,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 JIA ACR70 (n=42,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9"/>
                    <measurement group_id="O2" value="95.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 JIA ACR90 (n=42,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.0"/>
                    <measurement group_id="O2" value="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116 JIA ACR30 (n=41,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116 JIA ACR50 (n=41,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116 JIA ACR70 (n=41,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1"/>
                    <measurement group_id="O2" value="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116 JIA ACR90 (n=41,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.9"/>
                    <measurement group_id="O2" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 JIA ACR30 (n=39,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 JIA ACR50 (n=39,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 JIA ACR70 (n=39,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4"/>
                    <measurement group_id="O2" value="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 JIA ACR90 (n=39,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5"/>
                    <measurement group_id="O2" value="82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 JIA ACR30 (n=34,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 JIA ACR50 (n=34,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 JIA ACR70 (n=34,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 JIA ACR90 (n=34,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.5"/>
                    <measurement group_id="O2" value="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 JIA ACR30 (n=27,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 JIA ACR50 (n=27,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 JIA ACR70 (n=27,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 JIA ACR90 (n=27,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="78.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 JIA ACR30 (n=27,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 JIA ACR50 (n=27,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 JIA ACR70 (n=27,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6"/>
                    <measurement group_id="O2" value="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 JIA ACR90 (n=27,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 JIA ACR30 (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 JIA ACR50 (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 JIA ACR70 (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 JIA ACR90 (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6"/>
                    <measurement group_id="O2" value="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 JIA ACR30 (n=20,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 JIA ACR50 (n=20,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 JIA ACR70 (n=20,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0"/>
                    <measurement group_id="O2" value="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 JIA ACR90 (n=20,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0"/>
                    <measurement group_id="O2" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 JIA ACR30 (n=19,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 JIA ACR50 (n=19,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 JIA ACR70 (n=19,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7"/>
                    <measurement group_id="O2" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 JIA ACR90 (n=19,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.2"/>
                    <measurement group_id="O2" value="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 JIA ACR30 (n=18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 JIA ACR50 (n=18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 JIA ACR70 (n=18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 JIA ACR90 (n=18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 JIA ACR30 (n=17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 JIA ACR50 (n=17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 JIA ACR70 (n=17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 JIA ACR90 (n=17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.7"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 JIA ACR30 (n=16,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 JIA ACR50 (n=16,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 JIA ACR70 (n=16,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 JIA ACR90 (n=16,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8"/>
                    <measurement group_id="O2" value="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 JIA ACR30 (n=15,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 JIA ACR50 (n=15,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 JIA ACR70 (n=15,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7"/>
                    <measurement group_id="O2" value="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 JIA ACR90 (n=15,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="70.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 JIA ACR30 (n=15,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 JIA ACR50 (n=15,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 JIA ACR70 (n=15,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7"/>
                    <measurement group_id="O2" value="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 JIA ACR90 (n=15,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part III: Percentage of Participants Who Maintain JIA ACR30, JIA ACR50, JIA ACR70, JIA ACR90 Response for 6 Months Previous to the Specified Week</title>
        <description>JIA ACR core set consisting of 6 components: 1) Physician's global assessment of disease activity VAS, 2) Parent/Patient global assessment of overall well-being VAS, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate, and 6) CHAQ-DI consisting of 30 questions in 8 domains.</description>
        <time_frame>Weeks 104, 116, 128, 140, 152, 164, 176, 188, 200, 212, 224, 236, 248 and 260</time_frame>
        <population>The Part III ITT3 population</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants Treated With Tocilizumab</title>
            <description>Tocilizumab either 8 mg/kg (participants ≥ 30 kg) or 12 mg/kg (participants &lt;30 kg) iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part III: Percentage of Participants Who Maintain JIA ACR30, JIA ACR50, JIA ACR70, JIA ACR90 Response for 6 Months Previous to the Specified Week</title>
          <description>JIA ACR core set consisting of 6 components: 1) Physician's global assessment of disease activity VAS, 2) Parent/Patient global assessment of overall well-being VAS, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate, and 6) CHAQ-DI consisting of 30 questions in 8 domains.</description>
          <population>The Part III ITT3 population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 104 JIA ACR 30 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 104 is the start of Part III. The first 6 month maintenance data starts at Week 128 (24 weeks after Week 104)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 JIA ACR 50 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 104 is the start of Part III. The first 6 month maintenance data starts at Week 128 (24 weeks after Week 104)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 JIA ACR 70 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 104 is the start of Part III. The first 6 month maintenance data starts at Week 128 (24 weeks after Week 104)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 JIA ACR 90 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 104 is the start of Part III. The first 6 month maintenance data starts at Week 128 (24 weeks after Week 104)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116 JIA ACR 30 (n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 104 is the start of Part III. The first 6 month maintenance data starts at Week 128 (24 weeks after Week 104)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116 JIA ACR 50 (n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 104 is the start of Part III. The first 6 month maintenance data starts at Week 128 (24 weeks after Week 104)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116 JIA ACR 70 (n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 104 is the start of Part III. The first 6 month maintenance data starts at Week 128 (24 weeks after Week 104)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116 JIA ACR 90 (n=86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Week 104 is the start of Part III. The first 6 month maintenance data starts at Week 128 (24 weeks after Week 104)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 JIA ACR 30 (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 JIA ACR 50 (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 JIA ACR 70 (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 JIA ACR 90 (n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 JIA ACR30 (n=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 JIA ACR50 (n=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 JIA ACR70 (n=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 JIA ACR90 (n=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 JIA ACR30 (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 JIA ACR50 (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 JIA ACR70 (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 JIA ACR90 (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 JIA ACR30 (n=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 JIA ACR50 (n=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 JIA ACR70 (n=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 JIA ACR90 (n=51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 JIA ACR30 (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 JIA ACR50 (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 JIA ACR70 (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 JIA ACR90 (n=44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 JIA ACR30 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 JIA ACR50 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 JIA ACR70 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 JIA ACR90 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 JIA ACR30 (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 JIA ACR50 (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 JIA ACR70 (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 JIA ACR90 (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 JIA ACR30 (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 JIA ACR50 (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 JIA ACR70 (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 JIA ACR90 (n=36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 JIA ACR30 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 JIA ACR50 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 JIA ACR70 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 JIA ACR90 (n=35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 JIA ACR30 (n=33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 JIA ACR50 (n=33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 JIA ACR70 (n=33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 JIA ACR90 (n=33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 JIA ACR30 (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 JIA ACR50 (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 JIA ACR70 (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 JIA ACR90 (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 JIA ACR30 (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 JIA ACR50 (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 JIA ACR70 (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 JIA ACR90 (n=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part III: Doses of Oral Corticosteroids</title>
        <description>Oral corticosteroid values summarized are based on average daily dose on the nominal study day. The prednisone equivalent is used in calculation of oral corticosteroid dose. Participants who withdrew are excluded at the the visit of withdrawal and all subsequent visits.</description>
        <time_frame>Baseline and Weeks 104, 116, 128, 140, 152, 164, 176, 188, 200, 212, 224, 236, 248 and 260</time_frame>
        <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
        <group_list>
          <group group_id="O1">
            <title>Participants ≥30 kg</title>
            <description>Tocilizumab 8 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Participants &lt;30 kg</title>
            <description>Tocilizumab 12 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part III: Doses of Oral Corticosteroids</title>
          <description>Oral corticosteroid values summarized are based on average daily dose on the nominal study day. The prednisone equivalent is used in calculation of oral corticosteroid dose. Participants who withdrew are excluded at the the visit of withdrawal and all subsequent visits.</description>
          <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
          <units>mg/kg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=53,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.203" spread="0.1572"/>
                    <measurement group_id="O2" value="0.356" spread="0.1397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 (n=45,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020" spread="0.0455"/>
                    <measurement group_id="O2" value="0.047" spread="0.0869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116 (n=42,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.022" spread="0.0464"/>
                    <measurement group_id="O2" value="0.046" spread="0.0831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 (n=41,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.022" spread="0.0449"/>
                    <measurement group_id="O2" value="0.058" spread="0.1635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 (n=34,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.031" spread="0.0625"/>
                    <measurement group_id="O2" value="0.051" spread="0.1112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 (n=28,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.021" spread="0.0388"/>
                    <measurement group_id="O2" value="0.060" spread="0.1125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 (n=28,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018" spread="0.0349"/>
                    <measurement group_id="O2" value="0.068" spread="0.1179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 (n=25,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019" spread="0.0383"/>
                    <measurement group_id="O2" value="0.073" spread="0.1327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 (n=21,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020" spread="0.0366"/>
                    <measurement group_id="O2" value="0.075" spread="0.1275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 (n=20,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.017" spread="0.0284"/>
                    <measurement group_id="O2" value="0.083" spread="0.1397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 (n=19,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.016" spread="0.0274"/>
                    <measurement group_id="O2" value="0.077" spread="0.1449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 (n=18,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.017" spread="0.0279"/>
                    <measurement group_id="O2" value="0.075" spread="0.1399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 (n=17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.018" spread="0.0283"/>
                    <measurement group_id="O2" value="0.077" spread="0.1436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 (n=16,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020" spread="0.0290"/>
                    <measurement group_id="O2" value="0.076" spread="0.1429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 (n=16,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.019" spread="0.0282"/>
                    <measurement group_id="O2" value="0.079" spread="0.1486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part III: Percentage of Participants on Corticosteroids at Baseline Able to Discontinue Corticosteroids by Weeks 104,116, 128, 140, 152, 164, 176, 188, 200, 212, 224, 236, 248, and 260</title>
        <description>Values summarized are based on average daily dose on the nominal study day. The prednisone equivalent is used in calculation of oral corticosteroid dose. Participants who withdrew are excluded at the timepoint of this event and at all subsequent visits.
Baseline considered first dose of study treatment. Data presented up to entry into the Alternative Dosing Schedule.</description>
        <time_frame>Weeks 104,116, 128, 140, 152, 164, 176, 188, 200, 212, 224, 236, 248, and 260</time_frame>
        <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
        <group_list>
          <group group_id="O1">
            <title>Participants ≥30 kg</title>
            <description>Tocilizumab 8 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Participants &lt;30 kg</title>
            <description>Tocilizumab 12 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part III: Percentage of Participants on Corticosteroids at Baseline Able to Discontinue Corticosteroids by Weeks 104,116, 128, 140, 152, 164, 176, 188, 200, 212, 224, 236, 248, and 260</title>
          <description>Values summarized are based on average daily dose on the nominal study day. The prednisone equivalent is used in calculation of oral corticosteroid dose. Participants who withdrew are excluded at the timepoint of this event and at all subsequent visits.
Baseline considered first dose of study treatment. Data presented up to entry into the Alternative Dosing Schedule.</description>
          <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 104 (n=38,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0"/>
                    <measurement group_id="O2" value="67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116 (n=36,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0"/>
                    <measurement group_id="O2" value="68.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 (n=35,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0"/>
                    <measurement group_id="O2" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 (n=31,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 (n=25,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0"/>
                    <measurement group_id="O2" value="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 (n=25,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0"/>
                    <measurement group_id="O2" value="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0"/>
                    <measurement group_id="O2" value="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 (n=18,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0"/>
                    <measurement group_id="O2" value="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 (n=17,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0"/>
                    <measurement group_id="O2" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 (n=16,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0"/>
                    <measurement group_id="O2" value="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0"/>
                    <measurement group_id="O2" value="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0"/>
                    <measurement group_id="O2" value="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0"/>
                    <measurement group_id="O2" value="61.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part III: Percentage of Participants With a &gt;=20/50/75/90% Decrease From Baseline in Oral Corticosteroid Dose at Visits</title>
        <description>Values summarized are based on average daily dose on the nominal study day. The prednisone equivalent is used in calculation of oral corticosteroid dose. Participants who withdrew are excluded at the timepoint of this event and at all subsequent visits.
Baseline considered first dose of study treatment.</description>
        <time_frame>Every 2 weeks from Week 104 to Week 260</time_frame>
        <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
        <group_list>
          <group group_id="O1">
            <title>Participants ≥30 kg</title>
            <description>Tocilizumab 8 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Participants &lt;30 kg</title>
            <description>Tocilizumab 12 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part III: Percentage of Participants With a &gt;=20/50/75/90% Decrease From Baseline in Oral Corticosteroid Dose at Visits</title>
          <description>Values summarized are based on average daily dose on the nominal study day. The prednisone equivalent is used in calculation of oral corticosteroid dose. Participants who withdrew are excluded at the timepoint of this event and at all subsequent visits.
Baseline considered first dose of study treatment.</description>
          <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 104 &gt;20% decrease (n=38,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 &gt;50% decrease (n=38,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7"/>
                    <measurement group_id="O2" value="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 &gt;75% decrease (n=38,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2"/>
                    <measurement group_id="O2" value="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 &gt;90% decrease (n=38,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1"/>
                    <measurement group_id="O2" value="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 106 &gt;20% decrease (n=37,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 106 &gt;50% decrease (n=37,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.9"/>
                    <measurement group_id="O2" value="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 106 &gt;75% decrease (n=37,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8"/>
                    <measurement group_id="O2" value="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 106 &gt;90% decrease (n=37,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.3"/>
                    <measurement group_id="O2" value="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 &gt;20% decrease (n=37,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 &gt;50% decrease (n=37,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.2"/>
                    <measurement group_id="O2" value="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 &gt;75% decrease (n=37,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1"/>
                    <measurement group_id="O2" value="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108 &gt;90% decrease (n=37,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.3"/>
                    <measurement group_id="O2" value="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 110 &gt;20% decrease (n=36,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 110 &gt;50% decrease (n=36,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9"/>
                    <measurement group_id="O2" value="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 110 &gt;75% decrease (n=36,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6"/>
                    <measurement group_id="O2" value="84.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 110 &gt;90% decrease (n=36,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112 &gt;20% decrease (n=36,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112 &gt;50% decrease (n=36,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9"/>
                    <measurement group_id="O2" value="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112 &gt;75% decrease (n=36,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6"/>
                    <measurement group_id="O2" value="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 112 &gt;90% decrease (n=36,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 114 &gt;20% decrease (n=36,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 114 &gt;50% decrease (n=36,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9"/>
                    <measurement group_id="O2" value="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 114 &gt;75% decrease (n=36,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6"/>
                    <measurement group_id="O2" value="79.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 114 &gt;90% decrease (n=36,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116 &gt;20% decrease (n=35,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116 &gt;50% decrease (n=35,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4"/>
                    <measurement group_id="O2" value="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116 &gt;75% decrease (n=35,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="79.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116 &gt;90% decrease (n=35,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 118 &gt;20% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 118 &gt;50% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6"/>
                    <measurement group_id="O2" value="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 118 &gt;75% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 118 &gt;90% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 &gt;20% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 &gt;50% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6"/>
                    <measurement group_id="O2" value="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 &gt;75% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="83.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120 &gt;90% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3"/>
                    <measurement group_id="O2" value="76.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 122 &gt;20% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 122 &gt;50% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6"/>
                    <measurement group_id="O2" value="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 122&gt;75% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1"/>
                    <measurement group_id="O2" value="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 122 &gt;90% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.3"/>
                    <measurement group_id="O2" value="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 124 &gt;20% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 124 &gt;50% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3"/>
                    <measurement group_id="O2" value="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 124 &gt;75% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="83.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 124 &gt;90% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1"/>
                    <measurement group_id="O2" value="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 126 &gt;20% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 126 &gt;50% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3"/>
                    <measurement group_id="O2" value="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 126 &gt;75% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 126 &gt;90% decrease (n=35,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1"/>
                    <measurement group_id="O2" value="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 &gt;20% decrease (n=35,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 &gt;50% decrease (n=35,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4"/>
                    <measurement group_id="O2" value="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 &gt;75% decrease (n=35,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 &gt;90% decrease (n=35,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1"/>
                    <measurement group_id="O2" value="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 130 &gt;20% decrease (n=35,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 130 &gt;50% decrease (n=35,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4"/>
                    <measurement group_id="O2" value="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 130 &gt;75% decrease (n=35,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 130 &gt;90% decrease (n=35,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="74.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 &gt;20% decrease (n=35,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 &gt;50% decrease (n=35,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4"/>
                    <measurement group_id="O2" value="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 &gt;75% decrease (n=35,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132 &gt;90% decrease (n=35,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 134 &gt;20% decrease (n=35,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3"/>
                    <measurement group_id="O2" value="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 134 &gt;50% decrease (n=35,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6"/>
                    <measurement group_id="O2" value="87.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 134 &gt;75% decrease (n=35,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1"/>
                    <measurement group_id="O2" value="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 134 &gt;90% decrease (n=35,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1"/>
                    <measurement group_id="O2" value="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 136 &gt;20% decrease (n=34,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1"/>
                    <measurement group_id="O2" value="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 136 &gt;50% decrease (n=34,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2"/>
                    <measurement group_id="O2" value="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 136 &gt;75% decrease (n=34,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5"/>
                    <measurement group_id="O2" value="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 136 &gt;90% decrease (n=34,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5"/>
                    <measurement group_id="O2" value="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 138 &gt;20% decrease (n=34,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1"/>
                    <measurement group_id="O2" value="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 138 &gt;50% decrease (n=34,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.2"/>
                    <measurement group_id="O2" value="89.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 138 &gt;75% decrease (n=34,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5"/>
                    <measurement group_id="O2" value="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 138 &gt;90% decrease (n=34,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5"/>
                    <measurement group_id="O2" value="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 &gt;20% decrease (n=29,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1"/>
                    <measurement group_id="O2" value="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 &gt;50% decrease (n=29,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 &gt;75% decrease (n=29,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 &gt;90% decrease (n=29,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 142 &gt;20% decrease (n=29,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1"/>
                    <measurement group_id="O2" value="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 142 &gt;50% decrease (n=29,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 142 &gt;75% decrease (n=29,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 142 &gt;90% decrease (n=29,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 &gt;20% decrease (n=28,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9"/>
                    <measurement group_id="O2" value="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 &gt;50% decrease (n=28,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 &gt;75% decrease (n=28,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144 &gt;90% decrease (n=28,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 146 &gt;20% decrease (n=28,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4"/>
                    <measurement group_id="O2" value="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 146 &gt;50% decrease (n=28,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9"/>
                    <measurement group_id="O2" value="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 146 &gt;75% decrease (n=28,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="80.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 146 &gt;90% decrease (n=28,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 148 &gt;20% decrease (n=27,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 148 &gt;50% decrease (n=27,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3"/>
                    <measurement group_id="O2" value="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 148 &gt;75% decrease (n=27,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8"/>
                    <measurement group_id="O2" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 148 &gt;90% decrease (n=27,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.1"/>
                    <measurement group_id="O2" value="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 150 &gt;20% decrease (n=25,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 150 &gt;50% decrease (n=25,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 150 &gt;75% decrease (n=25,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 150 &gt;90% decrease (n=25,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="68.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 &gt;20% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 &gt;50% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 &gt;75% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 &gt;90% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 154 &gt;20% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 154 &gt;50% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 154 &gt;75% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 154 &gt;90% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 &gt;20% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 &gt;50% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 &gt;75% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 156 &gt;90% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 158 &gt;20% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 158 &gt;50% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 158 &gt;75% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 158 &gt;90% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 160 &gt;20% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 160 &gt;50% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 160 &gt;75% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 160 &gt;90% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 162 &gt;20% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 162 &gt;50% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0"/>
                    <measurement group_id="O2" value="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 162 &gt;75% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 162 &gt;90% decrease (n=25,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0"/>
                    <measurement group_id="O2" value="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 &gt;20% decrease (n=24,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 &gt;50% decrease (n=24,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 &gt;75% decrease (n=24,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 &gt;90% decrease (n=24,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 166 &gt;20% decrease (n=24,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 166 &gt;50% decrease (n=24,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8"/>
                    <measurement group_id="O2" value="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 166 &gt;75% decrease (n=24,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 166 &gt;90% decrease (n=24,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 &gt;20% decrease (n=24,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 &gt;50% decrease (n=24,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8"/>
                    <measurement group_id="O2" value="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 &gt;75% decrease (n=24,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 168 &gt;90% decrease (n=24,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 170 &gt;20% decrease (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 170 &gt;50% decrease (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5"/>
                    <measurement group_id="O2" value="81.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 170 &gt;75% decrease (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3"/>
                    <measurement group_id="O2" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 170 &gt;90% decrease (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3"/>
                    <measurement group_id="O2" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 172 &gt;20% decrease (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 172 &gt;50% decrease (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 172 &gt;75% decrease (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3"/>
                    <measurement group_id="O2" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 172 &gt;90% decrease (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3"/>
                    <measurement group_id="O2" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 174 &gt;20% decrease (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 174 &gt;50% decrease (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 174 &gt;75% decrease (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3"/>
                    <measurement group_id="O2" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 174 &gt;90% decrease (n=22,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3"/>
                    <measurement group_id="O2" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 &gt;20% decrease (n=19,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 &gt;50% decrease (n=19,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 &gt;75% decrease (n=19,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7"/>
                    <measurement group_id="O2" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 &gt;90% decrease (n=19,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7"/>
                    <measurement group_id="O2" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 178 &gt;20% decrease (n=19,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 178 &gt;50% decrease (n=19,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 178 &gt;75% decrease (n=19,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7"/>
                    <measurement group_id="O2" value="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 178 &gt;90% decrease (n=19,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7"/>
                    <measurement group_id="O2" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 &gt;20% decrease (n=19,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 &gt;50% decrease (n=19,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 &gt;75% decrease (n=19,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7"/>
                    <measurement group_id="O2" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 180 &gt;90% decrease (n=19,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7"/>
                    <measurement group_id="O2" value="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 182 &gt;20% decrease (n=18,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 182 &gt;50% decrease (n=18,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 182 &gt;75% decrease (n=18,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 182 &gt;90% decrease (n=18,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 184 &gt;20% decrease (n=18,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 184 &gt;50% decrease (n=18,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                    <measurement group_id="O2" value="86.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 184 &gt;75% decrease (n=18,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 184 &gt;90% decrease (n=18,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 186 &gt;20% decrease (n=18,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 186 &gt;50% decrease (n=18,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                    <measurement group_id="O2" value="90.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 186 &gt;75% decrease (n=18,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 186 &gt;90% decrease (n=18,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 &gt;20% decrease (n=18,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 &gt;50% decrease (n=18,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                    <measurement group_id="O2" value="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 &gt;75% decrease (n=18,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 &gt;90% decrease (n=18,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="61.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 190 &gt;20% decrease (n=18,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 190 &gt;50% decrease (n=18,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                    <measurement group_id="O2" value="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 190 &gt;75% decrease (n=18,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 190 &gt;90% decrease (n=18,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="61.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 &gt;20% decrease (n=18,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="95.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 &gt;50% decrease (n=18,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                    <measurement group_id="O2" value="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 &gt;75% decrease (n=18,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 192 &gt;90% decrease (n=18,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="61.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 194 &gt;20% decrease (n=18,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 194 &gt;50% decrease (n=18,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                    <measurement group_id="O2" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 194 &gt;75% decrease (n=18,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 194 &gt;90% decrease (n=18,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 196 &gt;20% decrease (n=18,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 196 &gt;50% decrease (n=18,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                    <measurement group_id="O2" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 196 &gt;75% decrease (n=18,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 196 &gt;90% decrease (n=18,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 198 &gt;20% decrease (n=18,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 198 &gt;50% decrease (n=18,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                    <measurement group_id="O2" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 198 &gt;75% decrease (n=18,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 198 &gt;90% decrease (n=18,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.2"/>
                    <measurement group_id="O2" value="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 &gt;20% decrease (n=17,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 &gt;50% decrease (n=17,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1"/>
                    <measurement group_id="O2" value="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 &gt;75% decrease (n=17,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 &gt;90% decrease (n=17,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6"/>
                    <measurement group_id="O2" value="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 202 &gt;20% decrease (n=17,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 202 &gt;50% decrease (n=17,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1"/>
                    <measurement group_id="O2" value="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 202 &gt;75% decrease (n=17,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 202 &gt;90% decrease (n=17,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6"/>
                    <measurement group_id="O2" value="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204 &gt;20% decrease (n=17,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204 &gt;50% decrease (n=17,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1"/>
                    <measurement group_id="O2" value="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204 &gt;70% decrease (n=17,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 204 &gt;90% decrease (n=17,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6"/>
                    <measurement group_id="O2" value="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 206 &gt;20% decrease (n=16,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 206 &gt;50% decrease (n=16,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 206 &gt;75% decrease (n=16,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 206 &gt;90% decrease (n=16,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8"/>
                    <measurement group_id="O2" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 &gt;20% decrease (n=16,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 &gt;50% decrease (n=16,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                    <measurement group_id="O2" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 &gt;75% decrease (n=16,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 208 &gt;90% decrease (n=16,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8"/>
                    <measurement group_id="O2" value="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 210 &gt;20% decrease (n=16,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 210 &gt;50% decrease (n=16,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8"/>
                    <measurement group_id="O2" value="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 210 &gt;75% decrease (n=16,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3"/>
                    <measurement group_id="O2" value="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 210 &gt;90% decrease (n=16,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 &gt;20% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 &gt;50% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 &gt;75% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 &gt;90% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 214 &gt;20% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 214 &gt;50% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 214 &gt;75% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 214 &gt;90% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 &gt;20% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 &gt;50% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 &gt;75% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 216 &gt;90% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 218 &gt;20% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 218 &gt;50% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 218 &gt;75% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 218 &gt;90% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 220 &gt;20% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 220 &gt;50% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 220 &gt;75% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 220 &gt;90% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 222 &gt;20% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 222 &gt;50% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 222 &gt;75% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 222 &gt;90% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 &gt;20% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 &gt;50% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3"/>
                    <measurement group_id="O2" value="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 &gt;75% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 &gt;90% decrease (n=15,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 226 &gt;20% decrease (n=14,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 226 &gt;50% decrease (n=14,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9"/>
                    <measurement group_id="O2" value="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 226 &gt;75% decrease (n=14,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6"/>
                    <measurement group_id="O2" value="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 226 &gt;90% decrease (n=14,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 228 &gt;20% decrease (n=14,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 228 &gt;50% decrease (n=14,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9"/>
                    <measurement group_id="O2" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 228 &gt;75% decrease (n=14,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6"/>
                    <measurement group_id="O2" value="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 228 &gt;90% decrease (n=14,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 230 &gt;20% decrease (n=14,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 230 &gt;50% decrease (n=14,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9"/>
                    <measurement group_id="O2" value="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 230 &gt;75% decrease (n=14,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6"/>
                    <measurement group_id="O2" value="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 230 &gt;90% decrease (n=14,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 232 &gt;20% decrease (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 232 &gt;50% decrease (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 232 &gt;75% decrease (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 232 &gt;90% decrease (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 234 &gt;20% decrease (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 234 &gt;50% decrease (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 234 &gt;75% decrease (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 234 &gt;90% decrease (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 &gt;20% decrease (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 &gt;50% decrease (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 &gt;75% decrease (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 &gt;90% decrease (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 238 &gt;20% decrease (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 238 &gt;50% decrease (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 238 &gt;75% decrease (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 238 &gt;90% decrease (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 &gt;20% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 &gt;50% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 &gt;75% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 240 &gt;90% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 242 &gt;20% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 242 &gt;50% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 242 &gt;75% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 242 &gt;90% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 244 &gt;20% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 244 &gt;50% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 244 &gt;75% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 244 &gt;90% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 246 &gt;20% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 246 &gt;50% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 246 &gt;75% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 246 &gt;90% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 &gt;20% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 &gt;50% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 &gt;75% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 &gt;90% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 250 &gt;20% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 250 &gt;50% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 250 &gt;75% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 250 &gt;90% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 252 &gt;20% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 252 &gt;50% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 252 &gt;75% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 252 &gt;90% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 254 &gt;20% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 254 &gt;50% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 254 &gt;75% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 254 &gt;90% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 256 &gt;20% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 256 &gt;50% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 256 &gt;75% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 256 &gt;90% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 258 &gt;20% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 258 &gt;50% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 258 &gt;75% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 258 &gt;90% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 &gt;20% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 &gt;50% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3"/>
                    <measurement group_id="O2" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 &gt;75% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 &gt;90% decrease (n=13,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part III: Percentage of Participants With Inactive Disease</title>
        <description>Participants who previously withdrew are excluded.
Responders are participants who met all of the following criteria for inactive disease at the visit assessment day:
i. Number of active joints = 0. ii. Absence of lymphadenopathy, hepatomegaly or splenomegaly in the nearest non-missing physical examination prior to or after the week assessment day. This could include results outside of the time window.
iii. Absence of symptomatic serositis adverse event. iv. In the 14 days preceding the week assessment day no fever (temperature &gt;=37.5 C) or rash characteristic of sJIA.
v. Normal ESR as defined by an ESR &lt;20 mm/hr regardless of age and sex. vi. Physician global assessment VAS &lt;=10. LOCF rule applied to missing number of active joints, ESR and Physician global assessment VAS.
Data presented up to the point of entry into the Alternative Dosing Schedule.</description>
        <time_frame>Weeks 104, 116, 128, 140, 152, 164, 188, 200, 212, 224,236,248 and 260</time_frame>
        <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
        <group_list>
          <group group_id="O1">
            <title>Participants ≥30 kg</title>
            <description>Tocilizumab 8 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Participants &lt;30 kg</title>
            <description>Tocilizumab 12 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part III: Percentage of Participants With Inactive Disease</title>
          <description>Participants who previously withdrew are excluded.
Responders are participants who met all of the following criteria for inactive disease at the visit assessment day:
i. Number of active joints = 0. ii. Absence of lymphadenopathy, hepatomegaly or splenomegaly in the nearest non-missing physical examination prior to or after the week assessment day. This could include results outside of the time window.
iii. Absence of symptomatic serositis adverse event. iv. In the 14 days preceding the week assessment day no fever (temperature &gt;=37.5 C) or rash characteristic of sJIA.
v. Normal ESR as defined by an ESR &lt;20 mm/hr regardless of age and sex. vi. Physician global assessment VAS &lt;=10. LOCF rule applied to missing number of active joints, ESR and Physician global assessment VAS.
Data presented up to the point of entry into the Alternative Dosing Schedule.</description>
          <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 104 (n=42,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2"/>
                    <measurement group_id="O2" value="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 116 (n=41,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8"/>
                    <measurement group_id="O2" value="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 (n=40,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0"/>
                    <measurement group_id="O2" value="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 (n=38,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3"/>
                    <measurement group_id="O2" value="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 (n=27,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 (n=27,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0"/>
                    <measurement group_id="O2" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 (n=24,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 (n=21,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                    <measurement group_id="O2" value="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 (n=19,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 (n=18,18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 (n=17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1"/>
                    <measurement group_id="O2" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 (n=16,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8"/>
                    <measurement group_id="O2" value="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 (n=15,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 (n=15,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7"/>
                    <measurement group_id="O2" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part III: Percentage of Participants in Clinical Remission</title>
        <description>Patients who previously withdrew are excluded Responders are patients who met all of the following criteria for inactive disease at all visits in the 6 months (180 days) prior to and including the visit assessment day: i. Number of active joints = 0. ii. Absence of lymphadenopathy, hepatomegaly or splenomegaly in the nearest non-missing physical examination prior to or after the week assessment day. This could include results outside of the time window.
iii. Absence of symptomatic serositis adverse event. iv. In the 14 days preceding the week assessment day no fever (temperature &gt;=37.5 C) or rash characteristic of sJIA. v. Normal ESR as defined by an ESR &lt;20 mm/hr regardless of age and sex.
vi. iv. Physician global assessment VAS &lt;=10. LOCF rule applied to missing number of active joints, ESR and Physician global assessment VAS. ESR = Erythrocyte Sedimentation Rate. VAS = Visual Analogue Scale. Data presented up to the point of entry into the Alternative Dosing Schedule.</description>
        <time_frame>Weeks 116, 128, 140, 152, 164, 188, 200, 212, 224,236,248 and 260</time_frame>
        <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
        <group_list>
          <group group_id="O1">
            <title>Participants ≥30 kg</title>
            <description>Tocilizumab 8 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Participants &lt;30 kg</title>
            <description>Tocilizumab 12 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part III: Percentage of Participants in Clinical Remission</title>
          <description>Patients who previously withdrew are excluded Responders are patients who met all of the following criteria for inactive disease at all visits in the 6 months (180 days) prior to and including the visit assessment day: i. Number of active joints = 0. ii. Absence of lymphadenopathy, hepatomegaly or splenomegaly in the nearest non-missing physical examination prior to or after the week assessment day. This could include results outside of the time window.
iii. Absence of symptomatic serositis adverse event. iv. In the 14 days preceding the week assessment day no fever (temperature &gt;=37.5 C) or rash characteristic of sJIA. v. Normal ESR as defined by an ESR &lt;20 mm/hr regardless of age and sex.
vi. iv. Physician global assessment VAS &lt;=10. LOCF rule applied to missing number of active joints, ESR and Physician global assessment VAS. ESR = Erythrocyte Sedimentation Rate. VAS = Visual Analogue Scale. Data presented up to the point of entry into the Alternative Dosing Schedule.</description>
          <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 116 (n=41,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 (n=40,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                    <measurement group_id="O2" value="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 (n=38,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2"/>
                    <measurement group_id="O2" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 (n=27,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9"/>
                    <measurement group_id="O2" value="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 (n=27,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 (n=24,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 (n=21,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 (n=19,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 (n=18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 (n=17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4"/>
                    <measurement group_id="O2" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 (n=16,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 (n=15,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 (n=15,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part III: Percentage of Participants on Corticosteroids at Baseline in Clinical Remission Off All Oral Corticosteroids for 6 Months Prior to Specified Visits</title>
        <description>There were 4 levels of clinical remission defined while the patient remained on tocilizumab as defined below.. After level 1, each successive level required that all the previous level criteria be met:
Level 1: inactive disease criteria have been met at all assessments in the last 6 months (180 days) preceding the timepoint assessment day Level 2: level 1 criteria and no oral corticosteroids received in the last 6 months (180 days) preceding the timepoint assessment day Level 3: level 2 criteria and no methotrexate received in the last 6 months (180 days) preceding the timepoint assessment day Level 4: level 3 criteria and no NSAIDs received for sJIA in the last 6 months (180 days) preceding the timepoint assessment day</description>
        <time_frame>Weeks 116, 128, 140, 152, 164, 188, 200, 212, 224,236,248 and 260</time_frame>
        <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
        <group_list>
          <group group_id="O1">
            <title>Participants ≥30 kg</title>
            <description>Tocilizumab 8 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Participants &lt;30 kg</title>
            <description>Tocilizumab 12 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part III: Percentage of Participants on Corticosteroids at Baseline in Clinical Remission Off All Oral Corticosteroids for 6 Months Prior to Specified Visits</title>
          <description>There were 4 levels of clinical remission defined while the patient remained on tocilizumab as defined below.. After level 1, each successive level required that all the previous level criteria be met:
Level 1: inactive disease criteria have been met at all assessments in the last 6 months (180 days) preceding the timepoint assessment day Level 2: level 1 criteria and no oral corticosteroids received in the last 6 months (180 days) preceding the timepoint assessment day Level 3: level 2 criteria and no methotrexate received in the last 6 months (180 days) preceding the timepoint assessment day Level 4: level 3 criteria and no NSAIDs received for sJIA in the last 6 months (180 days) preceding the timepoint assessment day</description>
          <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 116 (n=41,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 (n=40,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                    <measurement group_id="O2" value="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 (n=38,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 (n=27,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 (n=27,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 (n=24,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 (n=21,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 (n=19,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 (n=18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 (n=17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                    <measurement group_id="O2" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 (n=16,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 (n=15,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 (n=15,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part III: Percentage of Participants on Methotrexate At Baseline in Clinical Remission Off Corticosteroids and Methotrexate for 6 Months Prior to Specified Visits</title>
        <description>There were 4 levels of clinical remission defined while the patient remained on tocilizumab as defined below.. After level 1, each successive level required that all the previous level criteria be met:
Level 1: inactive disease criteria have been met at all assessments in the last 6 months (180 days) preceding the timepoint assessment day Level 2: level 1 criteria and no oral corticosteroids received in the last 6 months (180 days) preceding the timepoint assessment day Level 3: level 2 criteria and no methotrexate received in the last 6 months (180 days) preceding the timepoint assessment day Level 4: level 3 criteria and no NSAIDs received for sJIA in the last 6 months (180 days) preceding the timepoint assessment day</description>
        <time_frame>Weeks 116, 128, 140, 152, 164, 188, 200, 212, 224,236,248 and 260</time_frame>
        <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
        <group_list>
          <group group_id="O1">
            <title>Participants ≥30 kg</title>
            <description>Tocilizumab 8 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Participants &lt;30 kg</title>
            <description>Tocilizumab 12 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part III: Percentage of Participants on Methotrexate At Baseline in Clinical Remission Off Corticosteroids and Methotrexate for 6 Months Prior to Specified Visits</title>
          <description>There were 4 levels of clinical remission defined while the patient remained on tocilizumab as defined below.. After level 1, each successive level required that all the previous level criteria be met:
Level 1: inactive disease criteria have been met at all assessments in the last 6 months (180 days) preceding the timepoint assessment day Level 2: level 1 criteria and no oral corticosteroids received in the last 6 months (180 days) preceding the timepoint assessment day Level 3: level 2 criteria and no methotrexate received in the last 6 months (180 days) preceding the timepoint assessment day Level 4: level 3 criteria and no NSAIDs received for sJIA in the last 6 months (180 days) preceding the timepoint assessment day</description>
          <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 116 (n=41,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 (n=40,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 (n=38,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 (n=27,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 (n=27,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 (n=24,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 (n=21,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 (n=19,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 (n=18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 (n=17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 (n=16,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 (n=15,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 (n=15,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part III: Percentage of Participants in Clinical Remission Off All Arthritis Medications Except Tocilizumab for 6 Months Prior to Specified Visits</title>
        <description>There were 4 levels of clinical remission defined while the patient remained on tocilizumab as defined below.. After level 1, each successive level required that all the previous level criteria be met:
Level 1: inactive disease criteria have been met at all assessments in the last 6 months (180 days) preceding the timepoint assessment day Level 2: level 1 criteria and no oral corticosteroids received in the last 6 months (180 days) preceding the timepoint assessment day Level 3: level 2 criteria and no methotrexate received in the last 6 months (180 days) preceding the timepoint assessment day Level 4: level 3 criteria and no NSAIDs received for sJIA in the last 6 months (180 days) preceding the timepoint assessment day</description>
        <time_frame>Weeks 116, 128, 140, 152, 164, 188, 200, 212, 224,236,248 and 260</time_frame>
        <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
        <group_list>
          <group group_id="O1">
            <title>Participants ≥30 kg</title>
            <description>Tocilizumab 8 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Participants &lt;30 kg</title>
            <description>Tocilizumab 12 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part III: Percentage of Participants in Clinical Remission Off All Arthritis Medications Except Tocilizumab for 6 Months Prior to Specified Visits</title>
          <description>There were 4 levels of clinical remission defined while the patient remained on tocilizumab as defined below.. After level 1, each successive level required that all the previous level criteria be met:
Level 1: inactive disease criteria have been met at all assessments in the last 6 months (180 days) preceding the timepoint assessment day Level 2: level 1 criteria and no oral corticosteroids received in the last 6 months (180 days) preceding the timepoint assessment day Level 3: level 2 criteria and no methotrexate received in the last 6 months (180 days) preceding the timepoint assessment day Level 4: level 3 criteria and no NSAIDs received for sJIA in the last 6 months (180 days) preceding the timepoint assessment day</description>
          <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 116 (n=41,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 128 (n=40,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 140 (n=38,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 152 (n=27,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 164 (n=27,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 176 (n=24,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 188 (n=21,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 200 (n=19,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 212 (n=18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 224 (n=17,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 236 (n=16,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 248 (n=15,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 260 (n=15,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part III: Percentage of Participants Who Developed Antibodies To Tocilizumab During Weeks 104 to 260</title>
        <description>Human antibodies against human antibodies (HAHA), anti-tocilizumab antibodies were assessed by immunogenicity techniques from blood samples drawn every two weeks during Part III of the study.</description>
        <time_frame>Every 2 weeks from Week 104 to 260</time_frame>
        <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
        <group_list>
          <group group_id="O1">
            <title>Participants ≥30 kg</title>
            <description>Tocilizumab 8 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Participants &lt;30 kg</title>
            <description>Tocilizumab 12 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part III: Percentage of Participants Who Developed Antibodies To Tocilizumab During Weeks 104 to 260</title>
          <description>Human antibodies against human antibodies (HAHA), anti-tocilizumab antibodies were assessed by immunogenicity techniques from blood samples drawn every two weeks during Part III of the study.</description>
          <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part III: Percentage of Participants Who Developed Anti-TCZ Antibodies Associated With The Occurrence of Drug Hypersensitivity Reactions.</title>
        <description>Human antibodies against human antibodies (HAHA), anti-tocilizumab antibodies were assessed by immunogenicity techniques from blood samples drawn every two weeks during Part III of the study.</description>
        <time_frame>Every 2 weeks from Week 104 to 260</time_frame>
        <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
        <group_list>
          <group group_id="O1">
            <title>Participants ≥30 kg</title>
            <description>Tocilizumab 8 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
          <group group_id="O2">
            <title>Participants &lt;30 kg</title>
            <description>Tocilizumab 12 mg/kg iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.
Participants remained on their prescribed standard of care treatment with NSAIDs, methotrexate and corticosteroids if applicable.</description>
          </group>
        </group_list>
        <measure>
          <title>Part III: Percentage of Participants Who Developed Anti-TCZ Antibodies Associated With The Occurrence of Drug Hypersensitivity Reactions.</title>
          <description>Human antibodies against human antibodies (HAHA), anti-tocilizumab antibodies were assessed by immunogenicity techniques from blood samples drawn every two weeks during Part III of the study.</description>
          <population>ITT3 population; n=number of participants contributing to the specific statistic</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE onset between time of very first drug intake and date of last contact or 30 days after very last drug intake. 30 days after 12 weeks of treatment in Part I, 30 days after up to Week 104 in Part II and 30 days after up to Week 260 in Part III .</time_frame>
      <desc>Note: Adverse Events (AEs) reported in the All Tocilizumab (Part I, Part II and Part III) arm are cumulative to Week 260 and include AEs previously reported in the Tocilizumab_8 mg/kg (Part I) and Tocilizumab_12 mg/kg (Part I) arms that occurred in the 12 week treatment period.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Tocilizumab (Part I, Part II and Part III)</title>
          <description>Tocilizumab either 8 mg/kg (participants ≥ 30 kg) or 12 mg/kg (participants &lt;30 kg) iv every 2 weeks for 12 weeks in Part I, every 2 weeks for 92 weeks in Part II and every 2 weeks for 156 weeks in Part III.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Histiocytosis haematophagic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Lymphadenitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (14.0)">Abdominal pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Diarrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (14.0)">Drug intolerance</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (14.0)">Anaphylactic reaction</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.0)">Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Device related sepsis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Lower respiratory tract infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Pharyngitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Pulmonary tuberculosis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Varicella</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Spinal fracture</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Tendon rupture</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Hyperkalaemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Juvenile idiopathic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (14.0)">Acute Lymphocytic leukaemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (14.0)">Pregnancy</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Self injurious behavior</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular torsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pulmonary veno-occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.0)">Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.68</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.0)">Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Lymphadenopathy</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Lymphadenitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (14.0)">Ear pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (14.0)">Cataract</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.0)">Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Dental Caries</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Abdominal discomfort</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.0)">Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Local swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.0)">Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Cellulitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Skin infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Varicella</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Ligament Sprain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Arthropod bite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Hand fracture</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Infusion related reaction</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Thermal burn</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Neutrophil count decreased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.0)">Juvenile idiopathic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Back pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Joint Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Arthritis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Musculoskeletal stiffness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Osteoporosis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.0)">Headache</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Migraine</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.0)">Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.0)">Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.0)">Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (12.0)">Cough</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Rhinorrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (12.0)">Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Dry skin</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Pruritus</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Dermatitis atopic</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (14.0)">Erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study consists of 3 parts:
Part I: a 12 week double-blind placebo controlled study is complete. Part II: a 92 week single arm open-label extension study- CSR completed Dec. 2011.
Part III: a 3 year open label continuation study is ongoing.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffman-LaRoche</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

